CARLSBAD, Calif. & BOSTON--(BUSINESS WIRE)--The seventh annual BioPharm America™ international life science partnering conference wrapped up last week, September 22–24, at Boston Marriott Copley Place in the center of Boston’s historic Back Bay.
The event was attended by close to 900 high-level delegates representing 511 companies from 38 countries who engaged in 2,343 one-to-one partnering meetings with 787 licensing opportunities at BioPharm America. Biotech and pharma executives attended to identify and enter into strategic relationships that ultimately drive the multibillion dollar drug development industry. In addition, there were 73 company presentations.
BioPharm America in particular is a strategic business development opportunity for executives from emerging innovator and startup biotech companies. Three days of intensive one-to-one partnering meetings, facilitated by partneringONE®, were the focus of the event, along with panels featuring industry executives from the life science sector.
“We continue to see the number of licensing opportunities increase at BioPharm America,” said Anna Chrisman, Group Managing Director of EBD Group. “This is representative of the character of the event, which has a strong focus on new and innovative companies, especially in the Boston area. The event was extremely successful in bringing those opportunities to potential partners to benefit patients as future therapies and cures.”
“BioPharm America continues to draw a diverse group of industry leaders from around the world for productive partnering meetings,” said Robert K. Coughlin, President and CEO of MassBio. “These meetings are essential for the growth of our industry and the development of new treatments because, as we’ve seen increasingly over the past few years, collaboration is critical for the future of innovation here in Massachusetts and around the world.”
A highlight of the event was the live announcement of the biotech’s most daring characters in biopharma, the “Fierce 15,” by John Carroll, Editor-in-Chief of FierceBiotech. The Fierce 15 winners represent fifteen privately held drug developers or platform biotechs with the potential to have a huge impact on the treatment of human diseases. The LIVE Stream announcement of the Fierce 15 at BioPharm America™ 2014 can be replayed for a limited time on partnering360:Insight.
BioPharm America is produced by EBD Group in collaboration with the Massachusetts Biotechnology Council (MassBio) to facilitate strategic collaborations with leading companies. One-to-one networking at BioPharm America™ is powered by partneringONE®, the leading conference networking solution for the life sciences.
Full access to video coverage from BioPharm America 2014 is available on partnering360® | Insight. You can also keep the conversations going by joining partnering360®, the open online community of life science dealmakers.
To join the conversation:
Visit: BioPharm America™ webpage
Follow: @EBDGroup #BPA14
About BioPharm America 2014
BioPharm America™ is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Join partnering360® to kick off your partnering activities before BioPharm America, and throughout the year. partnering360 is a dynamic network of life science industry experts that will enable you to continue the dialogue from your partneringONE meetings at events and identify and connect with new partners anytime, year-round.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.